Neopharmed Gentili Completes Acquisition of European ORLADEYO® Business from BioCryst Pharmaceuticals
Acquisition Lays Foundation for Neopharmed Gentili European Rare Disease Powerhouse
MILAN, Italy, 1st October 2025 – Neopharmed Gentili S.p.A. (“Neopharmed”), a fast-growing Italian pharmaceutical company focused on high-value therapeutic solutions, today announced the successful closing of its acquisition of the European commercial operations for ORLADEYO® (berotralstat), a first-in-class oral treatment for hereditary angioedema (HAE), from BioCryst Pharmaceuticals, Inc.
This transaction marks a defining moment in Neopharmed’s strategic evolution, building on the company’s proven success in Italy to accelerate its expansion across Europe. It establishes a strong foundation for a leading rare disease powerhouse in the region. With ORLADEYO and the integration of BioCryst’s experienced European team, Neopharmed gains a scalable specialty platform—one that delivers immediate impact in the rare disease space and supports long-term growth across high-value, underserved therapeutic areas.
“This is more than a closing — it’s the beginning of a new chapter for us, aligning seamlessly with our ambition to scale our proven success in Italy, internationally,” said Alessandro Del Bono, President and CEO of Neopharmed Gentili. “We are laying the cornerstone of a European rare disease powerhouse, built on the strength of ORLADEYO, the expertise of a world-class team, and our ambition to deliver transformative therapies to patients across the continent.”
“I’d like to extend a heartfelt welcome to our new colleagues across Europe. I’m confident we share a strong commitment to achieving bold and meaningful goals together. I also want to express my sincere gratitude to the Neopharmed Gentili team for their dedication and support—your contributions have been vital to making this vision a reality,” continued Del Bono.
The acquisition includes full rights to ORLADEYO in Europe, a therapy approved in multiple countries and widely adopted by HAE patients seeking a convenient, effective oral option. The transaction also brings Neopharmed a rare disease business expected to grow over 30% year-onyear in 2025, generating approximately €50 million in sales, with significant long-term potential.
“We are proud to see ORLADEYO continue its success in Europe under Neopharmed Gentili’s leadership,” said Jon Stonehouse, CEO of BioCryst. “Their strategic vision and this robust platform make them an ideal partner for U.S. rare disease companies looking to expand into Europe. I’m confident that the infrastructure we’ve built, along with our exceptional team, will drive sustained success.”
Transaction Details
- Neopharmed has paid $250 million upfront for the European assets and rights related to ORLADEYO (subject to customary purchase price adjustments), with up to $14 million in future milestone payments tied to sales in Central and Eastern Europe.
- Neopharmed assumes responsibility for royalties related to European sales under BioCryst’s global royalty agreements.
- The transaction was funded through a combination of available cash and shareholder contributions.
Advisors
Centerview Partners UK LLP served as exclusive financial advisor, White & Case LLP as legal advisor, PwC as financial and tax advisor, ZS Associates as commercial advisor, and ValueVector as market access & pricing advisor to Neopharmed Gentili. BofA Securities, Inc. and TD Securities served as financial advisors, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to BioCryst.
About Neopharmed Gentili
Neopharmed Gentili is a rapidly growing Italian pharmaceutical company committed to delivering high-value therapeutic solutions across Europe. With a strong track record in M&A and strategic partnerships, the company is expanding its footprint in specialty and rare diseases. Guided by amission to improve patient outcomes through scientific excellence, ethical responsibility, and executional rigor, Neopharmed Gentili combines deep local roots with global ambition.
Neopharmed Gentili is privately owned by the Del Bono family, alongside global private equity firms Ardian and Renaissance Partners. For more information, visit www.neogen.it.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small molecule and protein therapies. For more information, please visit www.biocryst.com.
For further information, please contact:
Neopharmed Gentili S.p.A.
Ottavia Landi
Mob. 342.3409572 | o.landi@landi-consulting.com
Press office – Value Relations
Angela Del Giudice
Mob. 392.6858392 | a.delgiudice@vrelations.it
Chiara Farroni
Mob. 331.4997375 | c.farroni@vrelations.it
